Scarica l'app Stockscreener
126.15
2.96%
-3.85
Dopo l'orario di chiusura:
126.20
0.05
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$130.00
Aprire:
$129.89
Volume 24 ore:
10.31M
Relative Volume:
1.80
Capitalizzazione di mercato:
$219.56B
Reddito:
$43.84B
Utile/perdita netta:
$13.90B
Rapporto P/E:
15.82
EPS:
7.9725
Flusso di cassa netto:
$6.92B
1 W Prestazione:
-2.07%
1M Prestazione:
-1.86%
6M Prestazione:
-6.93%
1 anno Prestazione:
+7.70%
Intervallo 1D:
$124.58
$131.49
Intervallo di 1 settimana:
$124.58
$132.03
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.15 | 226.05B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.01 | 147.09B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.23 | 137.49B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.34 | 129.29B | 34.76B | 4.79B | 5.30B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
86.02 | 48.77B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports - WTAQ
Abbott is weighing takeover of Exact Sciences - ET HealthWorld
Why Exact Sciences Stock Blasted Nearly 24% Higher Today - The Motley Fool
Exact Sciences shares skyrocket amid reports of Abbott takeover - MassDevice
Chicago's Abbott Circles Cancer-Test Maker In Giant Deal Talks - Hoodline
Exact Sciences stock jumps on Abbott Labs acquisition speculation - Investing.com
Exact Sciences stock jumps on Abbott Labs acquisition speculation By Investing.com - Investing.com UK
Exact Sciences stock jumps on potential acquisition by Abbott - Investing.com UK
Abbott Labs stock rises on potential Exact Sciences acquisition talks - Investing.com India
Abbott Labs stock rises on potential Exact Sciences acquisition talks By Investing.com - Investing.com UK
Exact Sciences Stock Jumps on Reported Deal Interest from Abbott Laboratories - MSN
Exact Sciences could be sold to Abbott Laboratories, report says - Wisconsin State Journal
Exact Sciences shares soar on report Abbott is nearing deal for the company - Investing.com
Is Exact Sciences Getting A Deal? Shares Surge On Rumors. - Investor's Business Daily
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories - Barron's
Abbott Nears Deal for Cancer Test Maker Exact Sciences - Bloomberg.com
Stock Movers: Lowe's, Alphabet, Abbott Labs - Bloomberg.com
Abbott (ABT) Approaches Acquisition of Exact Sciences - GuruFocus
Exact Sciences (EXAS) Shares Surge on Potential Abbott Takeover - GuruFocus
Abbott nears deal to acquire Exact Sciences stock, William Blair reiterates Outperform - Investing.com
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories - MSN
Exact Sciences likely needs to see over $100/share in takeoveranalyst (EXAS:NASDAQ) - Seeking Alpha
Abbott in talks to buy exact sciences as cologuard maker’s shares jump - The Economic Times
Exact Sciences (EXAS) Surges on Potential Abbott Takeover - GuruFocus
Abbott (ABT) Moves Toward Acquiring Exact Sciences - GuruFocus
Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025 - ts2.tech
Exact Sciences shares soar on report Abbott is nearing deal for the company By Investing.com - Investing.com South Africa
Abbott weighs takeover of cancer test maker Exact Sciences, Bloomberg says - TipRanks
Exact Sciences jumps on report Abbott nears takeover (EXAS:NASDAQ) - Seeking Alpha
Is Abbott Laboratories (ABL) stock a safe buy pre earningsJuly 2025 Chart Watch & Verified Momentum Watchlists - newser.com
Can Abbott Laboratories (Common Stock) (ABL0) stock sustain margin levelsQuarterly Performance Summary & Risk Controlled Stock Pick Alerts - newser.com
Abbott Laboratories (NYSE:ABT) jumps 3.3% this week, though earnings growth is still tracking behind three-year shareholder returns - Yahoo Finance
Businesses have slowed at making commitments – but Abbott Labs is still planning to build in BG - BG Independent News
Sentiment analysis tools applied to Abbott LaboratoriesJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Is Abbott Laboratories (Common Stock) (ABL0) stock a top dividend aristocrat candidateWeekly Gains Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Assessing Abbott Laboratories (ABT) Valuation Potential After Recent Share Price Momentum - simplywall.st
Will earnings trigger a reversal in Abbott LaboratoriesWatch List & Weekly Breakout Stock Alerts - newser.com
Will Abbott Laboratories (ABL) stock benefit from infrastructure billQuarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com
Abbott Laboratories Stock: The Battle for the $140 Threshold - AD HOC NEWS
Can Abbott Laboratories stock surprise with earnings upsideBear Alert & AI Powered Buy and Sell Recommendations - newser.com
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report? - Yahoo Finance
What Does the Market Think About Abbott Laboratories? - Benzinga
Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Is Abbott Laboratories stock a buy on dipsMarket Performance Report & Daily Risk Controlled Trade Plans - newser.com
New data backs Abbott Aveir dual-chamber leadless pacemaker system - MassDevice
Here’s Why Abbott Laboratories (ABT) Traded Down in Q3 - Insider Monkey
Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
FDA expands urgent baby formula recall to all products made by one manufacturer - TheStreet
Citi Reaffirms Buy Rating on Abbott (ABT) Following Favorable Court Ruling - Insider Monkey
Abbott competitor's baby formula recalled after infant botulism outbreak - Crain's Chicago Business
Why pension funds invest in Abbott Laboratories (ABL) stockPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.23%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):